Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Change in Receivables (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Change in Receivables for 3 consecutive years, with -$12000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 97.89% to -$12000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$79000.0, a 92.36% increase, with the full-year FY2025 number at -$79000.0, up 92.36% from a year prior.
  • Change in Receivables was -$12000.0 for Q4 2025 at Artiva Biotherapeutics, down from $49000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $180000.0 in Q1 2024 to a low of -$645000.0 in Q2 2024.
  • A 3-year average of -$231222.2 and a median of -$204000.0 in 2025 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 97.89% in 2025; the steepest drop was 51.11% in 2025.
  • Artiva Biotherapeutics' Change in Receivables stood at -$614000.0 in 2023, then increased by 7.33% to -$569000.0 in 2024, then soared by 97.89% to -$12000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Change in Receivables are -$12000.0 (Q4 2025), $49000.0 (Q3 2025), and -$204000.0 (Q2 2025).